期刊文献+

经尿道电切术联合吉西他滨膀胱灌注治疗89例膀胱癌患者的临床疗效分析 被引量:10

下载PDF
导出
摘要 目的探讨经尿道电切术联合吉西他滨膀胱灌注治疗膀胱癌患者的临床疗效。方法本文选择本院2013年2月至2014年9月收治的89例患者随机分为观察组(n=45)和对照组(n=44)。两组均给予经尿道电切术,术后对照组采用吡柔比星膀胱灌注,治疗组采用吉西他滨膀胱灌注。观察比较两组术后复发、不良反应及生存质量情况。结果观察组1年复发率为2.22%,2年复发率6.67%,均明显低于对照组18.18%和27.27%(P<0.05)。治疗后,两组生存质量均显著提高(t=-13.006,P=0.000;t=-4.211,P=0.000);且观察组得分明显高于对照组(t=9.251,P=0.000)。观察组不良反应发生率35.56%,显著低于对照组的72.73%(χ2=12.372,P=0.000)。结论经尿道电切术联合吉西他滨膀胱灌注治疗膀胱癌临床疗效确切,可有效减少术后复发及不良反应发生率,提高患者生存质量,值得推广。
出处 《浙江创伤外科》 2017年第4期769-770,共2页 Zhejiang Journal of Traumatic Surgery
  • 相关文献

参考文献5

二级参考文献62

  • 1谢立平,毛祺琦.膀胱癌发病及影响预后的危险因素[J].临床外科杂志,2009,17(11). 被引量:7
  • 2Witjes JA.The impact of recurrent non-muscle-invasive bladder cancer on progression[J].Eur Urol,2013,63(1):155-157.
  • 3Brandau S.Local and systemic immune suppression in bladder cancer[J].J Urol,2007,177(1):12-13.
  • 4Sylvester RJ,van der Meijden AP,Oosterlinck W,et al.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC Risk Tables:A combined analysis of 2596 patients from seven EORTC trials[J].Eur Urol,2006,49(3):466-477.
  • 5Borkowska EM,Jedrzejczyk A,Marks P,et al.EORTC risk tables-their usefulness in the assessment of recurrence and progression risk in non muscle invasive bladder cancer in Polish patients[J].Cent European J Urol,2013,66(1):14-20.
  • 6Carballido J,Alvarezmon M,Soloverao J,et al.Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder[J].J Urol,1990,143(1):29-33.
  • 7Bunimovich-Mendrazitsky S,Claude Gluckman J,Chaskalovic J.A mathematical model of combined BCG and IL-2 immunotherapy of superficial bladder cancer[J].J Theor Biol,2011,277(1):27-40.
  • 8Vang DP,Wurz GT,Griffey SM,et al.Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice:a model for immunotherapy development[J].J Vis Exp,2013,30(80):e50868.
  • 9Breban R,Bisiaux A,Biot C,et al.Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immuneresponse[J].Oncoimmunology,2012,1(1):9-17.
  • 10Otto W,Denzinger S,Wieland WF,et al.First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma:CD3 positivity as a prognostic marker for cancer-specific survival[J].World J Urol,2012,30(6):875-877.

共引文献80

同被引文献58

引证文献10

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部